COMPANY PROFILE

InCarey

Explore full profile

Chain pharmacy providing specialty medicines for critical and chronic diseases

Hangzhou, ChinaFounded 2011Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About InCarey

InCarey operates in the healthcare sector, focusing on providing innovative solutions to enhance patient outcomes. The company serves a diverse range of clients including hospitals, clinics, and research institutions. InCarey leverages advanced research and cutting-edge technology to develop its products and services. The business model is centered around offering specialized healthcare solutions that address critical needs in the medical field. Revenue is generated through the sale of proprietary healthcare products, licensing of technology, and consulting services. InCarey is committed to continuous innovation and collaboration with leading healthcare providers to improve patient care.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Hangzhou, China
Employees: 3
Open positions: None listed
Dealroom signal: 25.0/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Dec 2021	$28M	$110M	Long Hill Capital · NEA	—
SERIES BOther financing	Sep 2020	$30M	$120M	Long Hill Capital	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

InCarey website traffic

Latest recorded traffic for InCarey is 890 monthly website visits, up 270.8% over the last three months. InCarey's team grew 0% over the past year.

Latest monthly visits890 3-month web change+270.8% 1-year team growth0%

Monthly website visitsOct 2020–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PHPharosiBioAI platform-based rarest-equivalent disease, a drug-developing company	Anyang-si, South Korea	Operational	5	$29M	$39M
3I310, Inc.Generative AI for large molecules	San Francisco, United States	Operational
MPMedi ProteinDesigns protein drugs and enzymes using quantum computing and machine learning	Delhi, India	Closed
MBMetaNovas BiotechCombines AI with cutting-edge science to decipher complex disease biology and discover effective medicines	Pudong, China	Operational
NENeurox1Target ID and drug discovery platform for neurological diseases	Austin, United States	Operational
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
OMOmicsChartPatient-centric cancer data and analytics platform for translational cancer biologists	Cardiff, United Kingdom	Operational
BTBiolexis TherapeuticsReimagines drug discovery with it's proprietary FIELDS Technology	Sandy, United States	Operational